
5æ³ãã11æ³ãžã®ã¯ã¯ãã³æ¥çš®ïœCDCã®ããŒã¿ããèªã¿åãå®å šæ§ïœ
5æ³ãã11æ³ãžã®æ°åã³ããã¯ã¯ãã³æ¥çš®ã«ã€ããŠã¯ãå»åž«ã«ãã£ãŠãæèŠãããããŠããŸããå æ¥ããã¬ãçªçµã§ã³ã¡ã³ãããŠããããå»åž«ã¯ããCDCïŒã¢ã¡ãªã«çŸç 察çã»ã³ã¿ãŒïŒã§ãå®å šã ãšããããŒã¿ãåºããŠããŸãããšãããããªããšãèšã£ãŠããŸãããã©ã®ããŒã¿ãã瀺ããã«æ¥çš®ãå§ããŠããŸããããæ¬åœã«å®å šã§ããããšã確èªã§ããããŒã¿ãªã®ã§ããããã
CDCãåºããŠããããŒã¿ã¯ã©ãã«ïŒ
å»åž«ã®ã³ã¡ã³ããèããããšãCDCã®ãµã€ãã調ã¹ãŠã¿ãã®ã§ããããã®ãšãã¯ã©ãã«ãããããããŸããã§ããã
ãã®åŸãå¥ã®èª¿ã¹ãã®ãããŠããããYahoo!ãã¥ãŒã¹ã«æ°ã«ãªãããŒã¿ããããŸããã
ã¹ã¯ããŒã«ããŠãããšããåã©ãã®æ¥çš®ãã«ã€ããŠæžãããŠããŸããã¢ã¡ãªã«ã§ãã¡ã€ã¶ãŒç€Ÿè£œã®ã¯ã¯ãã³ãæ¥çš®ãã5æ³ãã11æ³ã«è¡ã£ããå¯åå¿èª¿æ»ã®çµæã®ããã§ãã

ç±³CDCã«ãããšã2021幎11ïœ12æã®éã«ç±³åœã§5æ³ïœ11æ³ã®åã©ãã«æ°åã³ããã®ã¯ã¯ãã³ãçŽ870äžåæ¥çš®ããããã¡42,504åãèªçºçãªå¥åº·ç¶æ³èª¿æ»ã«å ±åããŸããããã®ãã¡æ¥çš®1åç®åŸã¯54.8ïŒ ããªãããã®å±æåå¿ã34.7ïŒ ãå šèº«ã®çç¶ã蚎ãããã®å²åã¯1åç®ãã2åç®ã®æ¹ãå€ãå ±åãããŠããŸããå€ãã£ãçç¶ã¯ãæ¥çš®éšã®çã¿ãã ãããé çãªã©ã§ãããçºç±ã¯1åç®åŸã7.9%ã2åç®åŸã¯13.4ïŒ ã§ããã
ãã®è¡šã«ã€ããŠã¯ã説æã¯ããã ãã§ããã2021幎11ïœ12æã®éã«ç±³åœã§çŽ870äžåæ¥çš®ããããšèšã£ãŠããŸããããã®ãã¡ã42,504åãèªçºçãªå¥åº·ç¶æ³èª¿æ»ã«å ±åããŸããããšãããŸããæ¥çš®ããåæ°ã®å²ã«ã¯ãå ±åãå°ãªãå°è±¡ã§ãã
ãããŠäžãã2çªç®ãšäžçªäžã«ããæ¥åžžçæŽ»ã«æ¯éããç»æ ¡ã§ããªãããšããã®ãæ°ã«ãªããŸããã§ãããã®è¡šã ãã§ã¯ããããã®çç¶ãäœæ¥ãããç¶ãããããããŸããã
衚ã®äžã«ãCOVID-19 Vaccine Safety in Children Aged 5â11 Years ïŒè±èªïŒãšæžãããŠããã®ã§ãå
ã®è³æãèŠããšCDCã®ãµã€ãã«ãããŸããã
ããããããããåè¿°ã®å»åž«ãèšã£ãŠããCDCã®ããŒã¿ãªã®ã ãšæãããŸãã
èªåã§æ¢ãããšãã§ããªãã£ãã®ã§ãããMMWRãšããè³æãæ¢ããšèŠã€ããããã§ãã

CDCãµã€ãã®ãããããŒãžãããäžã«ã¹ã¯ããŒã«ãããšMMWRãšãããããŒãèŠããŸãã
CDCãµã€ãããããããŒãž>MMWRãããŒ>COVID-19 ReportsãMoreãã¯ãªãã¯>å°ãäžã«ã¹ã¯ããŒã«ããŠã2021幎12æ31æ¥ãCOVID-19 Vaccine Safety in Children Aged 5â11 Years â United States, November 3âDecember 19, 2021
ããã§ã¯ãèªåã§ã¯ãšãŠããã©ãçããªããååŽçã®HPãšåããããããããã«ããã§ãã
COVID-19 Vaccine Safety in Children Aged 5â11 Years â United States, November 3âDecember 19, 2021
å ã®è³æã¯é·ãã§ãããå šæãäžèšã®ããŒãžã«ãããŸãã
CDCïŒã¢ã¡ãªã«çŸç 察çã»ã³ã¿ãŒïŒãåºããå ±åæžã¯ã5æ³ãã11æ³ã®å°å ã«çŽ870äžåæ¥çš®ãããPfizer-BioNTech COVID-19ã¯ã¯ãã³ã®æäžæéäžã«åéããããVAERSãšv-safeã®ããŒã¿ããåŸãããæå®³äºè±¡ããã³å¥åº·åœ±é¿è©äŸ¡ã«é¢ãããã®ã§ãã
VAERSãšã¯ãCDCãšFDAïŒã¢ã¡ãªã«é£åå»è¬åå±ïŒãå
±åã§éå¶ãããã¯ã¯ãã³æ¥çš®åŸã®æå®³äºè±¡ãç£èŠããååçãªã¯ã¯ãã³å®å
šæ§ç£èŠã·ã¹ãã ãå»çåŸäºè
ã ãã§ãªããã¯ã¯ãã³è£œé æ¥è
ãäžè¬åžæ°ãªã©ã誰ããã®å ±åãåãä»ããŠããããã§ãã
v-safeã®æ¹ã¯ãCDCãèšç«ãããã¹ããã䜿ã£ãŠå ±åã§ããã·ã¹ãã ãšã®ããšãä¿è·è
ãç»é²ãããšãæ¥çš®åŸã®èª¿æ»ã«ååã§ããããã§ãã
ã©ã¡ãããå ±åããããšæã£ã人ãç»é²ããããšæãããã®ã§ãäœããã®çç¶ãåºãŠããç»é²ããããšæããªããã°ãããŒã¿ã«ã¯å ¥ã£ãŠããªããšããããšã«ãªããšæããŸããã ãã870äžåãšããæ¥çš®åæ°ã®å²ã«ã¯ã調æ»å¯Ÿè±¡è ãå°ãªãã®ã§ãããã
VAERSãžã®å ±å

VAERSã¯2021幎11æ3æ¥ãã12æ19æ¥ã®éã«ãPfizer-BioNTech COVID-19ã¯ã¯ãã³ãæ¥çš®ãã5æ³ãã11æ³ã®å°å ã«é¢ããæå®³äºè±¡å ±åïŒè¡š1ïŒã4,249ä»¶åŠçãããšã®ããšãäººçš®ã»æ°æã«é¢ããããŒã¿ã¯ãçŽ40ïŒ ãäžæãšãªã£ãŠããŸãã

å ·äœçãªããŒã¿ïŒè¡š2ïŒã«ã€ããŠèª¬æãæžãããŠããŸãããé·ãã®ã§ç§ãæ°ã«ãªã£ãéšåã®ã¿ãåŒçšããŸãã
Among 15 preliminary reports of myocarditis identified during the analytic period, 11 were verified (by provider interview or medical record review) and met the case definition for myocarditis; of these 11 children, seven recovered, and four were recovering at time of the report. VAERS received two reports of death during the analytic period; both are under review. These deaths occurred in two females, aged 5 and 6 years, both of whom had complicated medical histories and were in fragile health before vaccination. None of the data suggested a causal association between death and vaccination.
åææéäžã«ç¢ºèªãããå¿ççãçãããå ±åïŒããããã³ã®äžæïŒ15ä»¶ã®ãã¡ã11ä»¶ã¯å»çæ©é¢ãªã©ã«ããæ€èšŒãããå¿ççã®çäŸå®çŸ©ã«åèŽããããã®11人ã®ãã¡ã7人ã¯å埩ãã4人ã¯å ±åæã«å埩ã«åãã£ãŠãããVAERSã¯åææéäžã«2ä»¶ã®æ»äº¡å ±åãåããããããããçŸåšèª¿æ»äžããããã®æ»äº¡äŸã¯5æ³ãš6æ³ã®å¥³æ§2åã§çºçãã2åãšãè€éãªç æŽãæã¡ãã¯ã¯ãã³æ¥çš®åã«è¡°åŒ±ããŠããããããã®ããŒã¿ããæ»äº¡ãšã¯ã¯ãã³æ¥çš®ã®å æé¢ä¿ã瀺åãããã®ã§ã¯ãªãã£ãã
å¿çççãã¯15ä»¶ã®å ±åãããããã®ãã¡11ä»¶ãå¿ççã®å®çŸ©ã«åèŽããŠãããšã®ããšãååŽçã®å¯åå¿çãã®å ±åã§ã¯ãæ¥çš®åŸã«ç¡çåæ§ã®å¿ççããã£ãã®ã§ãèªèŠçç¶ããªã人ãããå¯èœæ§ã¯ãããšæããŸããã¯ã¯ãã³æ¥çš®ãå§ãŸãåã¯ãå¿ççã¯ãã£ãšæãç æ°ã ãšãããŠããããã«æãã®ã§ãããå埩ããã°ãªã£ãŠããããšæãããããªç æ°ãªã®ã§ããããã
ãããŠã2ä»¶ãã£ãæ»äº¡å ±åã¯ãããããè€éãªç
æŽãæã£ãŠãããšã®ããšã§ãããã¯ã¯ãã³ãšã®å æé¢ä¿ã瀺åãããã®ã§ã¯ãªãããšããŠããŸãããè€éãªç
æŽãã©ã®ãããªãã®ã ã£ãã®ãã¯æžãããŠããŸããããã¬ãã«åºãŠããå»åž«ãå°éå®¶ã¯ãåºç€çŸæ£ãããåã©ããžã®æ¥çš®ãç¹ã«å§ããŠããŸããããã®ãããªããŒã¿ãæ€èšŒããªããŠããã®ã§ããããã
v-safeãžã®å ±å
Yahoo!ãã¥ãŒã¹ã§äœ¿ãããŠããããŒã¿ã¯ãv-safeã«ãã調æ»ã®ããŒã¿ã ã£ãããã§ãã

衚3ïŒ5ïœ11æ³ã®åã©ãïŒN = 42,504ïŒã§å ±åãããåå¿
0-7æ¥ç®ã«å°ãªããšã1åã®V-safe Health Check-in調æ»ãå®äºãã人
Pfizer-BioNTech COVID-19 ã¯ã¯ãã³æ¥çš®åŸ - ç±³åœ
2021幎11æ3æ¥ïœ12æ19æ¥
ïŒPercentage of enrollees who reported a reaction or health impact at least once during days 0â7 post-vaccination.
ã¯ã¯ãã³æ¥çš®åŸ0ïœ7æ¥ç®ã«å°ãªããšã1åãåå¿ãå¥åº·ãžã®åœ±é¿ãå ±åããç»é²è ã®å²åã
2021幎11æ3æ¥ãã12æ19æ¥ã®éã«ãv-safeã«ã¯ãPfizer-BioNTech COVID-19ã¯ã¯ãã³ãæ¥çš®ãã5ïœ11æ³ã®å°å
42,504人ãç»é²ãããããã§ããããããYahoo!ãã¥ãŒã¹ã«æžãããŠãã42,504人ã§ããã
ãã¡ããé·ãã®ã§ãæ°ã«ãªã£ãéšåã®ã¿ãåŒçšããŸãã
Approximately 5.1% of parents reported that their child was unable to perform normal daily activities on the day after receipt of dose 1, and 7.4% after receipt of dose 2.
æäž1åç®ã®ç¿æ¥ã«ãéåžžã®æ¥åžžç掻ãéããªãããšåçããä¿è·è ã¯çŽ5.1ïŒ ãæäž2åç®ã§ã¯çŽ7.4ïŒ ãšãããŸããç¿æ¥ã«çç¶ãåºãŠãããããã€ãŸã§ç¶ããã®ãã¯ããã§ã¯ããããŸãããæ¥æ°ã«ãã£ãŠã¯ãèŠéãããªãããŒã»ã³ãã ãšæããŸããååŽçãå ¬éããŠããå¯åå¿çãã®å ±åã§ã¯ãçæŽ»ã«æ¯éãåºãŠé·æã«ãããåŠæ ¡ã«è¡ããªãäºäŸã倿°ãããŸãã
Discussion
DiscussionïŒèå¯ïŒéšåã§ã¯ãäžèšã®ããã«æžãããŠããŸããããããæ°ã«ãªã£ãéšåã®ã¿ã®åŒçšã§ãã
Trial participants who received Pfizer-BioNTech COVID-19 vaccine frequently reported local (86.2%) and systemic (66.6%) reactions that were mostly mild (i.e., did not interfere with normal daily activities) or moderate (some interference with normal daily activities); no serious adverse events judged to be related to vaccination were reported (3).
å€ãã£ãå ±åã¯å±æåå¿ïŒ86.2%ïŒãå
šèº«åå¿ïŒ66.6%ïŒã§ãã»ãšãã©ã軜床ããäžçšåºŠïŒéåžžã®æ¥åžžæŽ»åã«å€å°ã®æ¯éãããïŒã ã£ããšãããŸããäžçšåºŠãšã¯ããããæ¥åžžæŽ»åã«å€å°ã®æ¯éãããããšããã®ããäœæ¥ããããŸã§ã ã£ãã®ããæ°ã«ãªããŸãã
ãã®éšåã§ç¹ã«éèŠãªã®ã¯ããã¯ã¯ãã³æ¥çš®ãšé¢ä¿ããããšå€æãããéç¯€ãªæå®³äºè±¡ã¯å ±åãããŠããŸããããšããéšåã ãšæããŸãããã®èª¿æ»ã®æç¹ã§ã¯ãé¢ä¿ãããããšå€æãããå ±åã¯ãªãããã©ããããããé¢ä¿ããªãããšèšãåãããšã¯éããŸãããååŽçã®ã¯ã¯ãã³Q&Aã®åçãšãããäŒŒãæžãæ¹ã§ãã
ããã£ãšæžãããŠããŸããããã®éšåãæ°ã«ãªããŸãã
Among VAERS reports for children aged 5â11 years who received Pfizer-BioNTech COVID-19 vaccine, approximately 97% were nonserious. The most common adverse events reported to VAERS in the age group were related to administration error. This age group is the first to receive a smaller dosage of mRNA (10 ÎŒg) than that recommended for persons aged â¥12 years (30 ÎŒg), and administration errors are not unexpected. Most reports of administration errors often mentioned that no adverse event was associated with receipt of an incorrect dose.
å ±åããããã¡ã®çŽ97ïŒ
ãéé節ã ã£ããšèšã£ãŠããŸãããããã®å¹Žéœ¢å±€ã§VAERSã«å ±åãããæå®³äºè±¡ã®äžã§æãå€ãã£ãã®ã¯ãæäžãã¹ã«é¢é£ãããã®ã ã£ãããšãæžãããŠããŸãã
衚2ã«ã¯ãIncorrect dose administeredïŒäžé©åãªæäžïŒã675ä»¶ïŒ16.3ïŒ
ïŒã
UnderdoseïŒééæäžïŒã324ä»¶ïŒ7.8ïŒ
ïŒãšãããŸãã
12æ³ä»¥äžçšããå°ãªãæäžéãåããŠåãã幎霢ã§ãããæäžãã¹ã¯èµ·ããåŸããšèšã£ãŠããŸããæäžãã¹ã®å ±åã¯ã»ãšãã©ããã誀ã£ãæäžéã«é¢é£ããæå®³äºè±¡ã¯ãªãã£ãããšã®ããšã§ãããä»åŸäœããã®çç¶ãåºãŠããå¯èœæ§ã¯ãŒãã§ã¯ãªããšæããŸãã

ãããŠããæäžãã¹ã¯èµ·ããåŸãããšèšã£ãŠããã®ã§ãæ¥æ¬ã§ãèµ·ããå¯èœæ§ã¯ããã§ãããã12æ³ä»¥äžã®æ¥çš®ã§ãããã§ã«æ¥çš®ãã¹ã¯å€çºããŠããŸãã
æåŸã«ãæãéèŠãšæãããèšè¿°ããããŸãã
The findings in this report are subject to at least four limitations. First, VAERS is a passive surveillance reporting system and is subject to reporting biases and underreporting, especially of nonserious events (8). Second, data on race/ethnicity were not provided in >40% of VAERS reports. Third, v-safe is a voluntary program; as a result, v-safe data might not be representative of the vaccinated population. Finally, these data are limited by the short surveillance period and might change as safety monitoring continues and more doses are administered to children aged 5â11 years.
ãã®å ±åã§åŸãããç¥èŠã«ã¯ããå°ãªããšã4ã€ã®éçãããããšèšã£ãŠããŸãã
1ïŒVAERSã¯ååçãªç£èŠå ±åã·ã¹ãã ã§ãããç¹ã«éé節ãªäºè±¡ã«ã€ããŠã¯ãå ±åãã€ã¢ã¹ãéå°å ±åã®å¯èœæ§ãããã
2ïŒäººçš®ã»æ°æã«é¢ããããŒã¿ã¯ãVAERSå ±åã®40ïŒ
以äžã«ãããŠæäŸãããŠããªãã
3ïŒV-safeã¯ä»»æã®ããã°ã©ã ã§ããããã®çµæãV-safeã®ããŒã¿ã¯ã¯ã¯ãã³æ¥çš®è
ã代衚ããŠããªãå¯èœæ§ãããã
4ïŒãããã®ããŒã¿ã¯çãç£èŠæéã«ããéããããã®ã§ãããå®å
šæ§ã®ç£èŠãç¶ç¶ããã5ïœ11æ³ã®å°å
ã«æäžãããåæ°ãå¢ããã«ã€ããŠå€åããå¯èœæ§ãããã
4ã€ããäžçªéèŠã ãšæããŸãããYahoo!ãã¥ãŒã¹ã§äœ¿ãããŠããV-safeã®ããŒã¿ã¯ããã¯ã¯ãã³æ¥çš®åŸ0ïœ7æ¥ç®ã«å°ãªããšã1åãå ±åããç»é²è ã®å²åã§ããå ±ååŸããããã©ããªã£ãã®ããããã®ããŒã¿ããã¯ããããŸããã
Yahoo!ãã¥ãŒã¹ã§ã¯200æåãããã§ãŸãšããŠããŸããããã®èæ¯ã«ã¯éèŠãªããšãåãããŠããŸããã
åè¿°ã®å»åž«ãèšã£ãŠããCDCãåºããŠããããŒã¿ãšããã®ãããã®ããšã ãšãããããã®ããŒã¿ãããªãå®å
šã ãšèšãåããã®ã§ããããã